TABLE 2.
Steady-state plasma concentrations of imatinib mesylate with 400 mg/d dose.
| Number | Mean concentrations (ng/ml) | Patients (numbers) | Assay | Country | References |
|---|---|---|---|---|---|
| 1 | 1,521.26 ± 610.33 | GIST, n = 168 | HPLC | China | Wu et al. (2018) |
| 2 | 1,398 ± 671 | GIST, n = 209 | LC-MS/MS | Korea | Koo et al. (2015) |
| 3 | 904.8 ± 795.2 | CML, n = 67 | HPLC | Japan | Takahashi et al. (2010) |
| 4 | 1,430.7 ± 438.7 | CML, n = 111 | LC-MS/MS | India | Francis et al. (2015) |
| 5 | 868 ± 536 | GIST, n = 96 | LC-MS/MS | France | Bouchet et al. (2016) |
| 6 | 1,332 ± 712 | GISTs, n = 69 | HPLC-MS | Norway | Hompland et al. (2016) |
| 7 | 1,193 (from 227 to 4,606) | GISTs, n = 108 | LC-MS | Netherlands | Farag et al. (2017) |
| 8 | 1,099 ± 156 | CML, n = 41 | LC-MS/MS | Belgium | Van Obbergh et al. (2017) |
| 9 | 800 (from 200 to 2,100) | CML, n = 24 | HPLC-MS | Italy | De Francia et al. (2014) |
| 10 | The mean concentration was missing; but 71.9 and 66.6% of men and women reported mean concentration ranging from 1,000 to 2,000 ng/ml, respectively | CML, n = 93 | HPLC-MS | United Kingdom | Belsey et al. (2017) |
CML, chronic myeloid leukemia; GISTs, gastrointestinal stromal tumors; HPLC, high-performance liquid chromatography; LC, liquid chromatography; MS, mass spectrometry.